Serving the Dry Eye Community
Surface Ophthalmics® is committed to improving the treatment of dry eye syndrome (DES) through its comprehensive pipeline of unique and patented medicinal candidates, encompassing both prescription (Rx) and over the counter (OTC) eye drops.
Underdiagnosed and Undertreated
Dry eye syndrome is a multifactorial ocular surface disease characterized by loss of tear film homeostasis and accompanied by symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.1 Dry eye syndrome can be naturally occurring or following ocular surgery.1
Only 1.7 million are using prescription therapies for their dry eye syndrome.2,3
Solutions in Development
Surface Ophthalmics® has treatments in development to address the entire range dry eye syndrome. This encompasses both episodic dry eye, which occurs intermittently, as well as chronic forms involving consistent symptoms. Our comprehensive portfolio aims to provide eyecare professionals (ECPs) multi-faceted solutions to tackle signs, symptoms, and underlying causes – not only in natural dry eye conditions but also for surgery-associated cases. With this full spectrum approach targeting the diversity of dry eye etiologies and presentations, we aim to empower ECPs with treatment options matching the needs of each unique patient.
About Us
Learn more about our company’s, mission, and history.
Leadership
View our experienced and talented group of team members.
News
Stay up to date on our latest announcements.
Transformative Potential
Surface Ophthalmics® has taken a diligent and thorough approach to building a proprietary and patented portfolio leveraging the learnings from the current treatment landscape and identifying solutions with the potential to meaningfully address shortfalls in today’s dry eye syndrome management options.
References:
- 1 Craig JP, et al., TFOS DEWS II Report Executive Summary, The Ocular Surface (2017)
- 2 2019 Dry Eye Products Market Report, Market Scope
- 3 Symphony Rx Data divided by DES Prevalence Study and validated with Market Scope data
- 4 White. Clin Ophthalmol. 2019